A股異動 | 朗姿股份漲6% 第三季淨利同比增22.37%
格隆匯11月2日丨朗姿股份(002612.SZ)現漲6.01%,報41.62元,總市值184億元,股價創超3個月新高。朗姿股份10月30日發佈2021三季報,公司主營收入26.51億元,同比上升32.75%;歸母淨利潤1.58億元,同比上升216.07%。其中2021年第三季度,公司單季度主營收入8.61億元,同比上升12.19%;單季度歸母淨利潤6469.92萬元,同比上升22.37%。國盛證券發研報稱,公司盈利能力逐季提升,女裝業務恢復增長。看好公司在醫美領域的擴張速度及運營能力,持續穩步推進以女裝、醫美和嬰童為主業的泛時尚產業互聯生態圈戰略,維持“增持”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.